Finance Roundup: Tizona, Aspyrian Raise VC Cash; Two Biotechs Ready IPOs

Immuno-oncology and targeted cancer therapies, especially when backed by seasoned drug development teams, continue to attract keen venture capital interest, as Tizona Therapeutics Inc. and Aspyrian Therapeutics Inc. demonstrated recently.

Immuno-oncology and targeted cancer therapies, especially when backed by seasoned drug development teams, continue to attract keen venture capital interest, as Tizona Therapeutics Inc. and Aspyrian Therapeutics Inc. demonstrated recently.

South San Francisco-based Tizona closed a $43m Series B round co-led by Canaan Partners and Abingworth to take its immuno-oncology...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.